ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cariprazine

Also written as “Cariprazine”, “MP-214 3mg” and “MP-214 6mg”.

Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Bipolar Disorder · Mania · Depression, led by 7 companies.

Drug pageCariprazine: every studyMany companies study it; this page follows only the 41 they lead. All 53 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jan 27, 201041 company-led studies, 4 open or runningNext primary completion: Dec 15, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only291 open or runningphase 3since Jan 27, 2010Nov 27, 2006Mar 2027phase 3 · NCT04777357
Tanabe Pharmaits history only60 open or runningphase 3since Jun 19, 2012Mar 15, 2009none ahead
Gedeon Richter Plc.21 open or runningphase 3since Jan 24, 2019Jun 13, 2014Dec 15, 2026phase 3 · NCT03817502
Bostal Drug Deliveryits history only11 open or runningphase 3since Jul 15, 2026Jul 15, 2026Aug 2027phase 3 · NCT07722728
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Jul 1, 2026Jul 1, 2026none ahead
Mapi Pharmaits history only11 open or runningphase 2since Aug 28, 2025Aug 28, 2025Dec 31, 2026phase 2 · NCT07185815
Whanin Pharmaceuticalits history only10 open or runningphase 3since Nov 26, 2021Nov 26, 2021none ahead

Also a collaborator on its studies: Gedeon Richter.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gedeon Richter Plc. only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 13, 2014First study: phase 1 study in Pharmacokinetic ProfileFirst studyNCT02165098 · 160 enrolled · United Kingdom
  2. Jan 24, 2019Phase 3 study in SchizophreniaNCT03817502 · 330 planned · United States, Bulgaria, Colombia and more

Ahead

  1. Dec 15, 2026Primary completion: phase 3 study in SchizophreniaNCT03817502

TargetBeta

DRD2 →DRD3 →read by rule
“Dopamine D3 receptor modulator; Dopamine D2 receptor modulator”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
OlanzapineruleEli Lillyphase 476
rotigotineruleUCBphase 464
PramipexoleruleBoehringer Ingelheimphase 444
ABBV-932AbbViephase 210

Studies

All 2 Gedeon Richter Plc. leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03817502Schizophrenia · United States, Bulgaria, Colombia and more3RecruitingDec 15, 2026330
NCT02165098Pharmacokinetic Profile · United Kingdom1CompletedFeb 2016160

How it is read

Names in the registry

  • “Cariprazine”, 25 entries
  • “MP-214 3mg”, 3 entries
  • “MP-214 6mg”, 3 entries
  • “MP-214 9mg”, 3 entries
  • “MP-214”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.